SillaJen initiates Phase 1/2 Clinical Trial of pexastimogene devacirepvec
Clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, SillaJen declared the commencement of Phase 1/2 clinical trial of…
Read More...
Read More...
